UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

editorial-team@simplywallst.com (Simply Wall St)
1 min read
0
In this article:

UroGen Pharma (NASDAQ:URGN) Full Year 2023 Results

Key Financial Results

  • Revenue: US$82.7m (up 28% from FY 2022).

  • Net loss: US$102.2m (loss narrowed by 6.9% from FY 2022).

  • US$3.55 loss per share (improved from US$4.81 loss in FY 2022).

URGN Products In Clinical Trials

  • Phase I: 3.

  • Phase III: 1.

revenue-and-expenses-breakdown
revenue-and-expenses-breakdown

All figures shown in the chart above are for the trailing 12 month (TTM) period

UroGen Pharma Revenues Beat Expectations

Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) was mostly in line with analyst estimates.

In the last 12 months, the only revenue segment was Biotechnology (Startups) contributing US$82.7m. The largest operating expense was General & Administrative costs, amounting to US$93.3m (53% of total expenses). Explore how URGN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 20% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for UroGen Pharma (1 makes us a bit uncomfortable!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Advertisement

Recommended Stories